![]() ![]() ![]() "Insurance providers stand on the side of the patient," he added. There is no reason any patient should face higher out-of-pocket costs for branded drugs unless the pharmaceutical manufacturer arbitrarily decides to cut off copay assistance to patients." "If patients do pay more for branded drugs, it will only be because pharmaceutical manufacturers impose limits on the amount of copay assistance they are willing to provide. The accumulators "can help insurers better reflect actual patient out-of-pocket costs," said Allen, of AHIP. They're growing, and it's really bad policy." "The insurance companies are double-billing because they're collecting all that coupon money and now they're collecting from the patient. ![]() "Patients don't know this is happening, and they're picking up the drug thinking their copay assistance is counting, and all of a sudden they get stuck with a $1,000 bill," he said in a phone interview. "The way it works is really damaging to patients," agreed Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. The NPC is a health policy research organization funded by pharmaceutical firms. "They think they've met the total amount and then they're surprised when the plan says, 'We've accumulated all those coupons and they don't count for out-of-pocket costs,'" Jennifer Graff, vice president for policy research at the National Pharmaceutical Council (NPC), said during a phone interview at which a public relations person was present. These rules can be confusing for patients, who may be unaware of the practice. Often, insurers won't allow the money paid by drugmakers to count toward the patient's deductible or out-of-pocket costs. Insurers are notified when their patients use copay coupons, and many of them use the data to compile "copay accumulator" records for enrollees. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |